APOC2 and hyperlipidemia: To test whether hematopoietic defects are a direct result of hyperlipidemia, we treated apoc2 mutants with lomitapide, an inhibitor of microsomal triglyceride transfer protein, which reduces very low-density lipoprotein (VLDL) formation and is used as a lipid-lowering drug for treatment of familial hypercholesterolemia patients.